In 2760 patients with acute pulmonary embolism or proximal DVT randomised to apixaban or rivaroxaban for 3 months, clinically relevant bleeding occurred in 3.3% vs 7.1% of 2700 analysed (RR 0.46). Deaths were 0.1% vs 0.3%.
RCTn = 2,760
Castellucci et al. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism